'As required' medication regimens for seriously mentally ill people in hospital

Cochrane Database of Systematic Reviews

Volumn 2015, Issue 12, 2015, Pages

  Douglas Hall, Petrina ^a   Whicher, Emma V ^b  

^a SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^b Richmond Royal Hospital   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PSYCHOTROPIC AGENT; NEUROLEPTIC AGENT;

AGGRESSION; AGITATION; BEHAVIOR CHANGE; BEHAVIOR DISORDER; CONTROLLED STUDY; DELUSION; DISEASE SEVERITY; DISTRESS SYNDROME; GOOD CLINICAL PRACTICE; HALLUCINATION; HEALTH CARE COST; HEALTH CARE QUALITY; HOSPITAL PATIENT; HUMAN; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MENTAL DISEASE; MENTAL HEALTH; PATIENT CARE; PATIENT SATISFACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SYSTEMATIC REVIEW; HOSPITALIZATION; PRESCRIPTION; PSYCHOTIC DISORDERS;

ANTIPSYCHOTIC AGENTS; DRUG PRESCRIPTIONS; HOSPITALIZATION; HUMANS; PSYCHOTIC DISORDERS;

EID: 84965187574     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD003441.pub3     Document Type: Review

References (79)

1. Baker R, Kinon B, Liu H, Richey A, Hill A, Bergstrom R, et al. Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation. Journal of the European College of Neuropsychopharmacology 2002;12(Suppl 3):S256. [Hallo P.2.004]
2. Baker R, Kinon BJ, Liu H, Richey A, Hill AL, Bergstrom RF, et al. Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S127. [P.2.W.044]
3. Baker RW, Kinon B, Liu H, Schuh L, Bergstrom R, Hill A. Rapid initial dose escalation of oral olanzapine for acute agitation. 12th World Congress of Psychiatry; 2002 Aug 24-29; Yokohama, Japan. 2002. [MEDLINE: 11986138]
4. Baker RW, Kinon BJ, Liu H, Richey A, Hill AL, Bergstrom RF, et al. Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation. 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA. 2002. [No. 32]
5. Baker RW, Kinon BJ, Liu H, Richey A, Hill AL, Bergstrom RF, et al. Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation. Schizophrenia Research 2003;60:272.
6. Baker RW, Kinon BJ, Liu H, Richey A, Hill AL, Bergstrom RFP, et al. Effectiveness of rapid initial dose escalation of oral olanzapine for acute agitation. Schizophrenia Research 2002;53(3 Suppl 1):193. [14th Congress of the European College of Neuropsychopharmacology [Congress Information System]: Conifer, Excerpta Medica Medical Communications BV, 2001 P2084#]
7. Baker RW, Kinon BJ, Maguire GA, Liu H, Hill AL. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. Journal of Clinical Psychopharmacology 2003;23(4):342-8. [MEDLINE: 12920409]
8. Foster S, Kessel J, Berman ME, Simpson GM. Efficacy of lorazepam and haloperidol for rapid tranquillization in a psychiatric emergency room setting. International Clinical Psychopharmacology 1997;12(3):175-9. [MEDLINE: 97392142]
9. Hovens JE, Dries PJT, Melman CTM, Wapenaar RJC, Loonen AJM. Oral risperidone with lorazepam versus oral zuclopenthixol with lorazepam in the treatment of acute psychosis in emergency psychiatry: a prospective, comparative, open-label study. Journal of Psychopharmacology 2005;19(1):51-7. [PsycINFO 2006-04400-008]
10. Hovens JEJM, Beijeman S, Tollenaar J, Dries PJT, Loonen AJM. Risperidone versus zuclopentixol in acute psychosis in emergency psychiatry: a prospective naturalistic study. Journal of the European College of Neuropsychopharmacology 2003;13(4):S293. [P.2.035]
11. Huttunen MO, Tuhkanen H, Haavisto E, Nyholm R, Pitkanen M, Raitasuo V, et al. Low and standard dose depot haloperidol combined with targeted oral neuroleptics. Psychiatric Services 1996;47:83-5. [MEDLINE: 96402210]
12. Kinon B, Rotelli MD, Gilmore JA. Efficacy of olanzapine and adjunctive lorazepam to control agitation in schizophrenia. International Journal of Neuropsychopharmacology 2002;5(Suppl 1):S128. [P.2.W.046]
13. Kinon BJ, Ahl J, Rotelli MD, McMullen E. Efficacy of accelerated dose titration of olanzapine with adjunctive lorazepam to treat acute agitation in schizophrenia. American Journal of Emergency Medicine 2004;22(3):181-6. [MEDLINE: 15138953]
14. Kinon BJ, Wang L, Rotelli MD, Gilmore JA. The efficacy of olanzapine plus adjunctive lorazepam to control acute agitation in schizophrenia. European Neuropsychopharmacology 2001;11(3):278. [14th Congress of the European College of Neuropsychopharmacology [Congress Information System]: Conifer, Excerpta Medica Medical Communications BV, 2001 P2084#]
15. Kinon BJ, Stauffer VL, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Journal of Clinical Psychopharmacology 2008;28(6):601-7. [MEDLINE: 19011427]
16. Stauffer V, Kinon B, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Proceedings of the 161st Annual Meeting of the American Psychiatric Association; 2008 May 3-8; Washington DC, USA. 2008.
17. Kramer M, Roth T, Salis PJ, Zorick FJ. Relative efficacy and safety of loxapine succinate (Loxitane) and thioridazine hydrochloride (Mellaril) in the treatment of acute schizophrenia. Current Therapeutic Research 1978;23(5):619-31.
18. Lesem MD, Zajecka JM, Swift RH, Reeves KR, Harrigan EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. Journal of Clinical Psychiatry 2001;62(1):12-8.
19. Maoz G, Stein D, Meged S, Kurzman L, Levine J, Valevski A, et al. The anti-aggressive action of combined haloperidol-propranolol treatment in schizophrenia. European Psychologist 2000;5(4):312-25.
20. Neborsky RJ, Janowsky DS, Perel JM, Munson E, Depry D. Plasma-RBC haloperidol ratios and improvement in acute psychotic symptoms. Journal of Clinical Psychiatry 1984;45(1):10-3.
21. Potkin SG, Gharabawi GM, Greenspan AJ, Mahmoud R, Kosik-Gonzalez C, Rupnow MF, et al. A double-blind comparison of risperidone, quetiapine and placebo in patients with schizophrenia experiencing an acute exacerbation requiring hospitalisation. Schizophrenia Research 2006;85(1-3):254-65.
22. Slotnick VB. Management of the acutely agitated psychiatric patient with parental neuroleptics: the comparative symptom effectiveness profiles of haloperidol and chlorpromazine. 5th World Congress of Psychiatry; 1971 Nov 28-Dec 4, Ciudad de Mexico, Mexico. Mexico City: La Prensa Medica Mexicana, 1971:531. [Abstract Number; 1085]
23. Stotsky BA. Relative efficacy of parenteral haloperidol and thiothixene for the emergency treatment of acutely excited and agitated patients. Diseases of the Nervous System 1977;38(12):967-73. [MEDLINE: 78063782]
24. Zhang H, Wang G, Zhao J, Xie S, Xu X, Shi J, et al. Intramuscular ziprasidone versus haloperidol for managing agitation in Chinese patients with schizophrenia. Journal of Clinical Psychopharmacology 2013;33:178-85.
25. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200.
26. Asmal L, Flegar Srnka J, Wang J, Rummel-Kluge C, Komossa K, Leucht S. Quetiapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD006625.pub3]
27. Ayd FJ, Frank J. Problems with orders for medication as needed. American Journal of Psychiatry 1985;142(8):939-42.
28. Bagnall A-M, Kleijnen J, Leitner M, Lewis R. Ziprasidone for schizophrenia and severe mental illness. Cochrane Database of Systematic Reviews 2000, Issue 4. [DOI: 10.1002/14651858.CD001945]
29. Bland JM, Kerry SM. Trials randomised in clusters. BMJ 1997;315:600.
30. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique. 3: Comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
31. Bowden MF. Audit: prescription of 'as required' (p.r.n.) medication in an in-patient setting. Psychiatric Bulletin 1999;23:413-6.
32. Chakrabarti A, Bagnall A-M, Chue P, Fenton M, Palaniswamy V, Wong W, et al. Loxapine for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 4. [DOI: 10.1002/14651858.CD001943.pub2]
33. Craig TJ, Bracken J. An epidemiologic study of prn/stat medication use in a state psychiatric hospital. Annals of Clinical Psychiatry 1995;7(2):57-64.
34. Craven JL, Voore PM, Voineskos G. PRN medication for psychiatric inpatients. Canadian Journal of Psychiatry 1987;32(3):199-203.
35. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
36. Divine GW, Brown JT, Frazer LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7:623-9.
37. Dold M, Samara MT, Li C, Tardy M, Leucht S. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database of Systematic Reviews 2015, Issue 1. [DOI: 10.1002/14651858.CD009831.pub2]
38. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
39. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th Edition. American Psychiatric Publishing, 2013.
40. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple graphical test. BMJ 1997;315:629-34.
41. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
42. Fenton M, Rathbone J, Reilly J. Thioridazine for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD001944.pub2]
43. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
44. Gray R, Smedley N, Thomas B. The administration of PRN medication by mental health nurses. Journal of Psychiatric and Mental Health Nursing 1997;4(1):55-6.
45. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
46. Guy W. Clinical Global Impression (CGI). Early Clinical Drug eEvaluation (ECDEU) Assessment Manual for Psychopharmacology. Washington DC, USA: National Institute of Mental Health, 1976.
47. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
48. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]. The Cochrane Library. Chichester: John Wiley & Sons, Ltd, 2005, issue 3.
49. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
50. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. Journal of Psychopharmacology 2010;24(4 Suppl):81-90.
51. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
52. Juniper EF, Guyatt GH, Ferrie PJ, King DR. Sodium cromoglycate eye drops: regular versus "as needed" use in the treatment of seasonal allergic conjunctivitis. Journal of Allergy and Clinical Immunology 1994;94(1):36-43.
53. Jüni P, Altman DG, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001;323:42-6.
54. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. Multi-Health Systems: North Tonawanda, NY, 1986.
55. Khanna P, Suo T, Komossa K, Ma H, Rummel-Kluge C, El-Sayeh HG, et al. Aripiprazole versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2014, Issue 1. [DOI: 10.1002/14651858.CD006569.pub5]
56. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD006654.pub2]
57. Komossa K, Rummel-Kluge C, Schwarz S, Schmid F, Hunger H, Kissling W, et al. Risperidone versus other atypical antipsychotics for schizophrenia. Cochrane Database of Systematic Reviews 2011, Issue 1. [DOI: 10.1002/14651858.CD006626.pub2]
58. Lankappa S, Gandhi R. Quetiapine versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2012, Issue 7. [DOI: 10.1002/14651858.CD009935]
59. Leonard B. Fundamentals of Psychopharmacology. John Wiley & Sons, 1992.
60. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
61. Leucht C, Kitzmantel M, Kane J, Leucht S, Chua Wan Lian LC. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD004278.pub2]
62. Marder S, van Kammen D. Biological therapies. In: Sadock BJ, Sadock VA editor(s). Kaplan & Sadock's Comprehensive Textbook of Psychiatry. 7th Edition. Vol. 2, Philadelphia, London: Lippincott Williams & Wilkins, 2000:2376.
63. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
64. McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic Reviews 2008;30:67-76.
65. McLaren S, Browne FW, Taylor PJ. A study of psychotropic medication given 'as required' in a regional secure unit. British Journal of Psychiatry 1990;156:732-5.
66. Aronson J. Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions. 15th Edition. Vol. 1, Elsevier, 2006.
67. Milton J, Lawton J, Smith M, Buckley A. Hidden high-dose antipsychotic prescribing: effects of p.r.n. doses. Psychiatric Bulletin 1998;22:675-7.
68. Newton KL, Murthy R, Qureshi J. Antipsychotic prescribing in the light of the consensus statement of the College. Psychological Bulletin 1997;21(7):408-10.
69. Cunningham Owens DG, Johnson EC. Treatment and management of schizophrenia. In: López-Ibor JJ, Gelder MG, Andreasen NC editor(s). New Oxford Textbook of Psychiatry. Oxford: Oxford University Press, 2000:628-9.
70. Rattehalli Ranganath D, Jayaram Mahesh B, Smith M. Risperidone versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD006918.pub2]
71. Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-12.
72. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials 2010;11:32.
73. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 (available from www.cochrane-handbook.org).
74. Stahl S. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 3rd Edition. Cambridge University Press, 2008.
75. Stauffer V, Kinon B, Kollack-Walker S, Chen L, Sniadecki J. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Proceedings of the 161st Annual Meeting of the American Psychiatric Association. Washington DC, USA, 2008 May 3-8.
76. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
77. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
78. Chakrabarti A, Whicher EV, Morrison M, Douglas-Hall P. 'As required' medication regimens for seriously mentally ill people in hospital. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD003441.pub2]
79. Whicher E, Morrison M, Douglas-Hall P. 'As required' medication regimens for seriously mentally ill people in hospital. Cochrane Database of Systematic Reviews 2002, Issue 4. [DOI: 10.1002/14651858.CD003441]